An open-label, multi-institutional, randomized study to evaluate the additive effect of leukotriene receptor antagonist on cough score in patients with cough-variant asthma treated with inhaled corticosteroid

An open-label, multi-institutional, randomized study to evaluate the additive effect of leukotriene receptor antagonist on cough score in patients with cough-variant asthma treated with inhaled corticosteroid - Analysis of efficacy and safety of montelucast

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033398

Enrollment

Registered

2018-07-17

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cough-variant asthma

Interventions

inhaled corticosteroids plus leukotriene receptor antagonist inhaled corticosteroids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) age greater than 20; (2) dry cough continued for 3-weeks or more without wheezing; (3) cough responding to tulobuterol tapes; (4) normal respiratory function; (5) absence of rhinitis or sinusitis; (6) absence of symptom associated with gastroesophageal reflux disease; (7) not onset of respiratory infection within 3-weeks; and (8) no radiological findings

Exclusion criteria

Exclusion criteria: We excluded patients if they were diagnosed with bronchial asthma, atopic cough, sinobronchial syndrome, tuberculosis and lung cancer.

Design outcomes

Primary

Measure	Time frame
cough score and peak expiratory flow (PEF)	—

Countries

Japan

Contacts

Public ContactTatsuya Nagano

Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine

tnagano@med.kobe-u.a.jp0783825660

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026